{
    "clinical_study": {
        "@rank": "23209", 
        "acronym": "COR-ART", 
        "arm_group": [
            {
                "arm_group_label": "vanoxerine", 
                "arm_group_type": "Experimental", 
                "description": "vanoxerine oral capsule"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo to match vanoxerine oral capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo, in\n      a dose modification manner, on the conversion of symptomatic atrial fibrillation (a-fib) or\n      flutter of recent onset to normal sinus rhythm."
        }, 
        "brief_title": "Safety and Efficacy of Single Oral Doses of Vanoxerine for Conversion of Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Symptomatic Atrial Fibrillation", 
            "Atrial Flutter"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Atrial Flutter"
            ]
        }, 
        "detailed_description": {
            "textblock": "Vanoxerine has important antiarrhythmic properties and may prove effective in converting\n      AF/AFL to sinus rhythm in subjects with a history of AF.  This is a prospective, randomized,\n      double-blinded, placebo-controlled, dose-modifying study in subjects who have been in\n      symptomatic AF or AFL for more than 3 hours and less than 7 days as dated by symptoms, who\n      have AF/AFL documented on ECG at the time of study drug administration, and who satisfy the\n      inclusion and exclusion criteria.  The primary objectives of the trial are to evaluate the\n      safety and efficacy of a single oral dose of vanoxerine compared to placebo and to obtain\n      pharmacokinetic data for vanoxerine and its metabolite following oral administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  provide written informed consent,\n\n          -  male or female 18 years of age or greater; women of child bearing potential must use\n             adequate contraception\n\n          -  symptomatic AF/AFL for more than 3 hours and less than 7 days (168 hours), as dated\n             by symptoms\n\n          -  AF/AFL documented by ECG at the start of study drug administration\n\n        Exclusion Criteria:\n\n          -  Systolic blood pressure <100 mmHg.\n\n          -  Average heart rate <50 bpm.\n\n          -  Average QTcF (Fridericia correction) >440 ms.\n\n          -  Average QRS interval >140 ms.\n\n          -  Paced atrial or ventricular rhythm on ECG.\n\n          -  Serum potassium <3.5 meq/L (may be corrected prior to randomization).\n\n          -  Received another intravenous Class I or Class III antiarrhythmic drug within prior 3\n             days.\n\n          -  received amiodarone (oral or IV) in prior 3 months.\n\n          -  Clinical evidence or history of acute coronary syndrome within 30 days prior to\n             randomization.\n\n          -  Aortic stenosis with aortic valve area equal to or less than 1.0 cm2.\n\n          -  Rheumatic mitral stenosis with valve area of <1.5 cm2.\n\n          -  Untreated hyperthyroidism.\n\n          -  Acute pericarditis.\n\n          -  AF/AFL as a result of surgery within the last 7 days\n\n          -  History of failed electrical cardioversion\n\n          -  History of polymorphic ventricular tachycardia (PVT, e.g. torsades de pointes).\n\n          -  History or family history of long QT syndrome.\n\n          -  History of ventricular tachycardia requiring drug or device therapy.\n\n          -  History of NYHA Heart Failure Class 3 or 4 or recent (within 1 month) onset of heart\n             failure not related to rapid ventricular response AF.\n\n          -  Ejection fraction (EF) of 35% or less."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691313", 
            "org_study_id": "CRX-VN-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "vanoxerine", 
                "description": "single oral dose", 
                "intervention_name": "Vanoxerine", 
                "intervention_type": "Drug", 
                "other_name": "GBR12909"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "single oral dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vanoxerine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "vanoxerine", 
            "atrial fibrillation", 
            "atrial flutter", 
            "a-fib"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ashkelon", 
                        "country": "Israel"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haifa", 
                        "country": "Israel"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nazareth", 
                        "country": "Israel"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Safed", 
                        "country": "Israel"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Petersburg", 
                        "country": "Russian Federation"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Israel", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Multi-center, Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Oral Doses of Vanoxerine for Conversion of Subjects With Atrial Fibrillation or Flutter of Recent Onset to Normal Sinus Rhythm", 
        "overall_official": {
            "affiliation": "ChanRx Corp.", 
            "last_name": "Howard C Dittrich, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Israel: Ministry of Health", 
                "Russia: Ministry of Health of the Russian Federation"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "proportion of subjects who convert to sinus rhythm through 4 hours after start of study drug", 
            "measure": "conversion to sinus rhythm", 
            "safety_issue": "No", 
            "time_frame": "baseline through 4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691313"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "change in subject symptom score from baseline", 
            "measure": "subject symptom score", 
            "safety_issue": "No", 
            "time_frame": "baseline through 4 hours"
        }, 
        "source": "ChanRx Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ChanRx Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}